Features Partner Sites Information LinkXpress
Sign In
Demo Company

Restorative Gel Could Help Reverse Paralysis

By BiotechDaily International staff writers
Posted on 28 May 2013
Print article
A biodegradable implant that delivers a therapeutic gel could help restore healthy nerve function in degenerative disorders such as Parkinson's disease.

Researchers at Tel Aviv University (Israel) developed the implant, which is a soft, biodegradable tube that serves as a physical bridge to help the nerve ends connect. Lining the inside of the biodegradable tube is a guiding regeneration gel (GRG), a transparent, highly viscous, malleable, and adaptable gel that increases nerve growth and healing, helping the severed nerve ends to rejoin. But the GRG not only aids reconnection and cell preservation, it can also support their survival while being used for therapy and transplantation.

The key to the regeneration process lies in the composition of the gel, with three main components: superoxide dismutase (SOD) antioxidants, which exhibit high anti-inflammatory activities; synthetic laminin-derived peptides, which act as a railway or track for the nerve fibers to grow along; and hyaluronic acid, commonly found in the human fetus, which serves as a buffer against drying, a major danger for most implants. These components allow the nerve to heal the way a fetus does in the womb - quickly and smoothly.

Research to-date has shown that GRG stimulates cell growth, neuronal sprouting, and extracellular matrix (ECM) formation, supporting cells in vitro and in vivo upon implantation. It also supports three dimensional (3D) growth and differentiation of various cell types (embryonic, adult stem cells, and preneuronal cells). The implications for therapeutic applications include peripheral nerves reconstruction, cell therapy, corneal preservation, wound healing, and as a postirradiation tissue cavity filler.

“The implant has already been tested in animal models, and the gel by itself can be used as a stand-alone product, acting as an aid to cell therapy,” said GRG codeveloper Shimon Rochkind, MD. “When grown in the gel, cells show excellent development, as well as intensive fiber growth. This could have implications for the treatment of diseases such as Parkinson's.”

Related Links:

Tel Aviv University

Print article



view channel
Image: Glioblastoma multiforme (GBM) (Photo courtesy of the University of California, San Diego School of Medicine).

How Blocking TROY Signaling Slows Brain Cancer Growth

Cancer researchers have found how the low molecular weight drug propentofylline (PPF) slows the growth of the aggressive brain tumor glioblastoma multiforme (GBM). This form of brain cancer is the most... Read more


view channel
Image: A partially completed three-dimensional printed airway from nostril to trachea with fine structure of the nasal cavity showing (Photo courtesy of Dr. Rui Ni, Pennsylvania State University).

The Structure of the Nasal Cavity Channels Food Smells into the Nose and Avoids the Lungs

Three-dimensional printing technology was used to create a model of the nasal cavity that enabled researchers to demonstrate why the smell of food goes into the nose rather than down into the lungs.... Read more


view channel

Molecular Light Shed on “Dark” Cellular Receptors

Scientists have created a new research tool to help find homes for orphan cell-surface receptors, toward better understanding of cell signaling, developing new therapeutics, and determining causes of drug side-effects. The approach may be broadly useful for discovering interactions of orphan receptors with endogenous, naturally... Read more

Lab Technologies

view channel
Image:  The BioSpa 8 Automated Incubator (Photo courtesy of BioTek Instruments).

Smart Incubator System Automates Live Cell Assay Operations

A new instrument that automates laboratory workflow by linking microplate washers and dispensers with readers and imaging systems is now available for biotech and other life sciences researchers.... Read more


view channel

Purchase of Biopharmaceutical Company Will Boost Development of Nitroxyl-Based Cardiovascular Disease Drugs

A major international biopharmaceutical company has announced the acquisition of a private biotech company that specializes in the development of drugs for treatment of cardiovascular disease. Bristol-Myers Squibb Co. (New York, NY, USA) has initiated the process to buy Cardioxyl Pharmaceuticals Inc. (Chapel Hill, NC, USA).... Read more
Copyright © 2000-2015 Globetech Media. All rights reserved.